Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK

Diabetes, Obesity and Metabolism

Volumn 15, Issue 2, 2013, Pages 121-129

  Pollock, R F ^a   Muduma, G ^b   Valentine, W J ^a  

^a Ossian Health Economics and Communications   (Switzerland)

^b ALLERGAN PLC   (United States)

Author keywords

Bariatric surgery; Cost effectiveness; Dietary intervention; Obesity therapy; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN;

ADULT; ARTICLE; BARIATRIC SURGERY; COMORBIDITY; COMPUTER MODEL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; FEMALE; FOLLOW UP; GASTRIC BANDING; HEALTH CARE; HEALTH CARE COST; HEALTH INSURANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STANDARD; UNITED KINGDOM; VALIDATION PROCESS;

EID: 84871931531     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01692.x     Document Type: Article

References (42)

1. World Health Organization. Overweight and Obesity. Factsheet 311. Geneva: World Health Organization, 2006.
2. Craig R, Mindell J eds. Health Survey for England 2006. Latest Trends. A survey carried out for NHS The Information Centre, 2006.
3. Howel D. Trends in the prevalence of obesity and overweight in English adults by age and birth cohort, 1991-2006. Public Health Nutr 2011; 14: 27-33.
4. Zaninotto P, Head J, Stamatakis E, Wardle H, Mindell J. Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012. J Epidemiol Community Health 2009; 63: 140-146.
5. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997; 146: 214-222.
6. Resnick HE, Valsania P, Halter JB, Lin X. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health 2000; 54: 596-602.
7. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79.
8. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882-889.
9. Liu B, Balkwill A, Reeves G, Beral V, Million Women Study Collaborators. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ 2010; 340: c912.
10. Butland B, Jebb S, Kopelman P et al. Foresight Tackling Obesities: Future Choices - Project Report, 2nd edn. Available from URL: http://www.bis.gov.uk/assets/bispartners/foresight/docs/obesity/obesity_final_part1.pdf. Accessed 17 July 2011.
11. National Institute for Health and Clinical Excellence. Obesity: Guidance on Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. Guideline 43. Available from URL: http://www.nice.org.uk/CG43. Accessed 25 July 2011.
12. Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339-350.
13. Hofsø D, Nordstrand N, Johnson LK et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol 2010; 163: 735-745.
14. Lee WJ, Chong K, Ser KH et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011; 146: 143-148.
15. Dixon JB, O'Brien PE, Playfair J et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299: 316-323.
16. Palmer AJ, Roze S, Valentine WJ et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004; 20: S5-S26.
17. Palmer AJ, Roze S, Valentine W et al. Validation of the CORE Diabetes Model against Epidemiological and Clinical Studies. Curr Med Res Opin. 2004; 20: S27-S40.
18. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327-340.
19. The Health and Social Care Information Centre. Available from URL: http://www.ic.nhs.uk/statistics-and-data-collections/health-and-lifestyles. Accessed 18 July 2011.
20. Office for National Statistics. United Kingdom Census 2001. Available from URL: http://www.statistics.gov.uk/StatBase/Expodata/Spreadsheets/D6588.xls. Accessed 15 July 2011.
21. Currie CJ, Poole CD, Tetlow T, Holmes P, McEwan P. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007; 23: S33-S39.
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
23. Raymond NT, Varadhan L, Reynold DR, UK Asian Diabetes Study Retinopathy Study Group; et al. Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study. Diabetes Care 2009; 32: 410-415.
24. Ray JA, Boye KS, Yurgin N et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007; 23: 609-622.
25. Sjöström L, Narbro K, Sjöström CD, Swedish Obese Subjects Study; et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
26. Beaudet A, Palmer JL, Timlin L et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ. 2011; 14: 357-366.
27. The Health and Social Care Information Centre. Prescription Cost Analysis, England - 2010. Available from URL: http://www.ic.nhs.uk/pubs/prescostanalysis2010. Accessed 17 July 2011.
28. NHS Prescription Services. Drug Tariff June 2010. Available from URL: http://www.ppa.org.uk/edt/June_2010/mindex.htm. Accessed 15 July 2011.
29. Department of Health. NHS Payment by Results 2010-11 National Tariff Information. Available from URL: http://data.gov.uk/dataset/payment-by-results-2010-11-national-tariff-information. Accessed 27 July 2011.
30. Salem L, Devlin A, Sullivan SD, Flum DR. Cost-effectiveness analysis of laparoscopic gastric bypass, adjustable gastric banding, and nonoperative weight loss interventions. Surg Obes Relat Dis. 2008; 4: 26-32.
31. Office for National Statistics. Consumer Price Indices. Available from URL: http://www.statistics.gov.uk/statbase/tsdtables1.asp?vlnk=mm23. Accessed 27 July 2011.
32. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005; 14: 217-230.
33. National Institute for Health and Clinical Excellence. Guide to Methods of Technology Appraisal - NICE. 2004. Available from URL: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf. Accessed 8 July 2011.
34. Ikramuddin S, Klingman D, Swan T, Minshall ME. Cost-effectiveness of Roux-en-Y gastric bypass in type 2 diabetes patients. Am J Manag Care 2009; 15: 607-615.
35. Keating CL, Dixon JB, Moodie ML, Peeters A, Playfair J, O'Brien PE. Cost-efficacy of surgically induced weight loss for the management of type 2 diabetes: a randomized controlled trial. Diabetes Care 2009; 32: 580-584.
36. Keating CL, Dixon JB, Moodie ML et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care 2009; 32: 567-574.
37. Picot J, Jones J, Colquitt JL et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1-190, 215-357, iii-iv.
38. Centre for Clinical Practice. National Institute for Health and Clinical Excellence. Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG87ShortGuideline.pdf. Accessed July 2012.
39. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447.
40. Ratner RE, Maggs D, Nielsen LL et al. Long-term effects of exenatide therapy over 82weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; 8: 419-428.
41. Davis TM. Ethnic diversity in type 2 diabetes. Diabet Med. 2008; 25(Suppl 2): 52-56.
42. Bellary S, O'Hare JP, Raymond NT et al. Premature cardiovascular events and mortality in south Asians with type 2 diabetes in the United Kingdom Asian Diabetes Study - effect of ethnicity on risk. Curr Med Res Opin. 2010; 26: 1873-1879.